0.03
-31.22%
Close of 6 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Agentix
From its filings with the US Securities and Exchange Commission
Agentix is based in Dana Point, California and is incorporated in Nevada. Its shares trade on OTC under the ticker AGTX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 March 2023, it reported revenue of $0.
The Company was incorporated in the State of Nevada on April 18, 2013 and has established a fiscal year end of March 31. Effective June 17, 2019, we changed our name from FairWind Energy, Inc. to Agentix Corp. and to better reflect the new focus of our business. We are a clinical development stage corporation with a focus on pharmaceutical treatments in the metabolic disease space and have not yet generated or realized meaningful revenues from our business.
Until recently, our business plan focused on the design, engineering and manufacturing of composite products, specifically the supply products to the oil and gas industry. However, on May 28, 2020, entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with GSL Healthcare, Inc., a Nevada corporation (“GSL Healthcare”), and the holders of common stock of GSL Healthcare, which consisted of two stockholders. The closing date occurred on June 1, 2020.
Under the terms and conditions of the Share Exchange Agreement, the Company offered and sold 27,932,271 shares of common stock of the Company in consideration for all of the issued and outstanding shares of common stock of GSL Healthcare. The effect of the issuance is that former two GSL Healthcare shareholders now hold approximately 88.0% of the issued shares of common stock of the Company, and GSL Healthcare is now a wholly-owned subsidiary of the Company.
Quoted from its 10-K, filed 1 Jul 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 5 Aug 2015
- Website
- agentixcorp.com ↗
- Head office
- 32932 PACIFIC COAST HIGHWAY, DANA POINT, CA, 92629
- Incorporated in
- NV
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Riazul HudaChief Executive Officer, Chief Financial Officer, Director, since 2020
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Agentix Corp develops AGTX-2004 for obesity and Type 2 diabetes in animal models.
- Agentix Australia Pty Ltd supports global therapeutic development efforts.
- GSL Healthcare Inc. is a wholly owned subsidiary enhancing therapeutic pipelines.
Weaknesses
- Agentix Corp's IPO occurred in 2015, limiting recent market presence.
- The company focuses on metabolic diseases without expanding into other sectors.
- AGTX-2003 targets obesity but lacks human trial data for NAFLD.
Opportunities
- Agentix Corp could expand AGTX-2004 into Type 2 diabetes treatment markets.
- The endocannabinoid system research offers new therapeutic pathways.
- US biotechnology market growth supports metabolic disease drug development.
Threats
- Agentix Corp faces competition from established biotech firms in metabolic disease treatments.
- Regulatory hurdles may delay AGTX-2004 and AGTX-2003 approvals.
- The US biotech sector experiences high R&D costs and funding challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.